We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $208.8 · 15 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MSN
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day MSN
CLSA upgrades Charles River Laboratories International (CRL) - MSN
CLSA upgrades Charles River Laboratories International (CRL) MSN
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MSN
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors MSN
[Form 4] CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Insider Trading Activity - Stock Titan
[Form 4] CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Insider Trading Activity Stock Titan
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 05. | After market close (AMC) | $2.73 | — | — | $973.34M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 29. | Time TBD | — | $0.5 | — | — | $984.17M | Reported |
| FY2025 Q3 | 2024. 09. 28. | Time TBD | — | $4.37 | — | — | $3.05B | Reported |
| FY2025 Q2 | 2024. 06. 29. | Time TBD | — | $3.04 | — | — | $2.04B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 29. | CLSA | — | Upgrade | Hold → Outperform | — | CLSA: Hold → Outperform |
| 2026. 05. 08. | Barclays | — | Maintain | Overweight → Overweight | — | Barclays: Overweight |
| 2026. 05. 08. | Evercore ISI Group | — | Maintain | Outperform → Outperform | — | Evercore ISI Group: Outperform |
| 2026. 04. 15. | Barclays | — | Maintain | Overweight → Overweight | — | Barclays: Overweight |
| 2026. 04. 14. | JP Morgan | — | Maintain | Neutral → Neutral | — | JP Morgan: Neutral |
| 2026. 02. 26. | UBS | — | Maintain | Neutral → Neutral | — | UBS: Neutral |
As of FY2026Q1 · Source: SEC/DART + price data
No holdings data to show.